Introduction {#S0001}
============

Circular RNAs (circRNAs), a novel class of endogenous noncoding RNAs (ncRNAs), are generated from back-splicing events and are characterized by a covalently closed continuous loop without 5′ caps and 3′ poly (A) tails.[@CIT0001],[@CIT0002] Owing to the closed continuous loop structure, circRNAs can escape exonuclease-mediated degradation; therefore, they are more stable in blood or plasma than are microRNAs (miRNAs) and long noncoding RNAs (lncRNAs).[@CIT0003] CircRNAs acting as ''miRNA sponges" are involved in the initiation and progression of several types of cancer by binding to miRNAs.[@CIT0004] Moreover, recent studies have revealed that some circRNAs play significant roles in various kinds of cancer, including gastric cancer (GC), hepatocellular carcinoma (HCC), breast cancer (BC), colorectal cancer (CRC), and lung adenocarcinoma (LAC), among others.[@CIT0005] These findings indicate that circRNAs have the potential to serve as novel noninvasive diagnostic biomarkers for various cancers.

However, due to small sample sizes and study design limitations, research evidence for the diagnostic accuracy of circRNAs in cancer is inaccurate and inadequate. To address these shortcomings, we conducted a comprehensive systematic analysis of data from all relevant publications to investigate the relationship between circRNAs and cancer diagnosis.

Methods {#S0002}
=======

Literature search strategy {#S0002-S2001}
--------------------------

All potential literature in this meta-analysis was independently retrieved and screened by two researchers (GL and LS). A comprehensive and systematic search was conducted of the PubMed, Web of Science, Cochrane Library, Embase, CNKI, and IEEE online databases to identify eligible studies indexed through November 25, 2018. The search terms were as follows: "circular RNAs OR circRNAs" AND "cancer OR carcinoma OR tumor OR neoplasm" AND "sensitivity OR specificity OR ROC curve OR AUC OR diagnosis". In addition, the reference lists of the included articles were manually reviewed to identify additional relevant studies. As this study was based on previously published studies, no ethical approval or patient consent was required.

Selection criteria of reported research {#S0002-S2002}
---------------------------------------

The selection process in this meta-analysis was executed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.[@CIT0006] All eligible studies fulfilled the following inclusion criteria. 1) Studies had a definite diagnosis of human cancer made using circRNAs. 2) All cancer cases were confirmed by pathological examination. 3) CircRNAs expression was detected in serum, plasma, or cancer tissue with quantitative reverse transcription--polymerase chain reaction (qRT--PCR) or other methods. 4) Studies provided sufficient diagnostic parameters to calculate true positives (TP), false positives (FP), true negatives (TN), and false negatives (FN). The exclusion criteria included the following: 1) studies that did not satisfy the abovementioned inclusion criteria; 2) studies that were duplicate articles, reviews, animal studies, editorials, case reports, comments, and meta-analyses; 3) studies lacking sufficient data to construct a diagnostic 2 × 2 table.

Data extraction and quality assessment {#S0002-S2003}
--------------------------------------

Two researchers (GL and TH) carefully reviewed the full texts of all eligible studies and independently extracted the relevant data, including the first author's name, publication year, country, cancer type, circRNA profiles, specimen, detection method, sample size, cutoff values, area under the curve (AUC), sensitivity and specificity, etc. Furthermore, 2 × 2 tables were created using TP, FP, TN, and FN. Any disagreement among the authors was resolved through discussions with a third author (LS) until a consensus was reached.

Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) was used to appraise the risk of bias and applicability of the included studies using Review Manager 5.2 software.[@CIT0007] The QUADAS-2 tool consists of four key domains: patient selection, index test, reference standard, and flow and timing. The risk of bias and concerns regarding applicability were evaluated as "low", "high", or "unclear".

Statistical analysis {#S0002-S2004}
--------------------

Statistical analysis of the diagnostic tests was executed using Stata 14.0, Meta-DiSc 1.4, and Review Manager 5.2. *Q* tests and *I*^2^ statistics were used to estimate the heterogeneity caused by a non-threshold effect among the included articles. Either *P*\<0.10 or *I*^2^\>50% suggested the existence of substantial heterogeneity; in this study, a random-effects model was applied to quantify the pooled sensitivity, specificity, diagnostic odds ratio (DOR), positive likelihood ratio (PLR), negative likelihood ratio (NLR), and AUC, with corresponding 95% confidence intervals (CIs). Otherwise, a fixed-effects model was used. Spearman correlation analysis was conducted to verify the threshold effects. Moreover, subgroup analysis and meta-regression were applied to trace the sources of heterogeneity. Sensitivity analysis was performed to assess the stability of our analysis. Publication bias was evaluated with Deeks' funnel plots. All tests were two-sided and *P*\<0.05 was considered statistically significant.

Results {#S0003}
=======

Literature search and selection of studies {#S0003-S2001}
------------------------------------------

A total of 290 articles were systematically retrieved from the online databases. A total of 231 records remained after duplicates were removed. First, we roughly screened the titles and abstracts and eliminated 161 publications that were irrelevant to the topic. The remaining 70 articles were further examined by careful review of the full text; as a result, 46 articles were excluded. Finally, a total of 32 eligible studies from 24 articles[@CIT0008]-[@CIT0031] involving 3,016 participants were included in the meta-analysis. The flow diagram is shown in [Figure 1](#F0001){ref-type="fig"}.Figure 1Flow diagram of the study selection process.

Study characteristics {#S0003-S2002}
---------------------

The main characteristics of the studies are listed in [Table 1](#T0001){ref-type="table"}. This diagnostic meta-analysis analyzed 32 eligible studies from 24 articles involving 2,400 cases and 2,295 controls. All cancer cases were confirmed pathologically and the controls consisted of adjacent nontumorous tissue, noncancer tissue, or plasma from unaffected subjects. Specifically, tissue, plasma or saliva specimens were collected before treatment including radiotherapy, chemotherapy, and targeted therapy. The expression of circRNAs was detected by qRT--PCR. All studies referred to five different cancer types: gastric (GC, n=16), liver (HCC, n=7), breast (BC, n=3), colorectal (CRC, n=3), lung (LAC, n=2), and oral squamous cell carcinoma (OSCC, n=1).Table 1Main characteristics of the studies included in the meta-analysisAuthorYearcircRNAs profilesCancer\
typeSpecimenTest methodSample size\
(case/control)SensitivitySpecificityLi et al.[@CIT0008]2017hsa_circ_0000096GCTissuesqRT--PCR101/1010.8800.560Zhu et al.[@CIT0009]2017hsa_circ_0013958LACTissuesqRT--PCR49/490.7550.796hsa_circ_0013958LACPlasmaqRT--PCR30/300.6670.933Yin et al.[@CIT0010]2017hsa_circ_0001785BCPlasmaqRT--PCR20/200.7860.756hsa_circ_0108942BCPlasmaqRT--PCR20/200.8150.504hsa_circ_0068033BCPlasmaqRT--PCR20/200.7320.578Zhao et al.[@CIT0011]2017hsa_circ_0000181GCTissuesqRT--PCR115/1150.5390.852hsa_circ_0000181GCPlasmaqRT--PCR102/1050.9900.206Fu et al.[@CIT0012]2017hsa_circ_0003570HCCTissuesqRT--PCR107/1070.4490.868Li et al.[@CIT0013]2017hsa circ 0001649GCTissuesqRT--PCR76/760.7110.816Qin et al.[@CIT0014]2015hsa_circ_0001649HCCTissuesqRT--PCR89/890.8100.690Wang et al.[@CIT0015]2015hsa_circ_001988CRCTissuesqRT--PCR31/310.6800.730Yao et al.[@CIT0016]2017circZKSCAN1HCCTissuesqRT--PCR102/1020.8220.724Zhuo et al.[@CIT0017]2017circRNA0003906CRCTissuesqRT--PCR122/400.7250.803Li et al.[@CIT0018]2017hsa_circ_0001017GCPlasmaqRT--PCR121/1210.9740.811hsa_circ_0061276GCPlasmaqRT--PCR121/1210.9030.517Shang et al.[@CIT0019]2016hsa_circ_0005075HCCTissuesqRT--PCR30/300.8330.900Li et al.[@CIT0020]2015hsa_circ_002059GCTissuesqRT--PCR101/1010.8100.620Chen et al.[@CIT0021]2017hsa_circ_0000190GCTissuesqRT--PCR104/1040.7210.683hsa_circ_0000190GCPlasmaqRT--PCR104/1040.4140.875Huang et al.[@CIT0022]2017hsa_circ_0000745GCPlasmaqRT--PCR60/600.8550.450Lu et al.[@CIT0023]2017hsa_circ_0006633GCTissuesqRT--PCR96/960.6000.810Sun et al.[@CIT0024]2017hsa_circ_0000520GCTissuesqRT--PCR56/560.5360.857hsa_circ_0000521GCPlasmaqRT--PCR45/170.8240.844Tian et al.[@CIT0025]2017hsa_circ_0003159GCTissuesqRT--PCR108/1080.8520.565Lu et al.[@CIT0026]2018hsa_circ_0000467GCPlasmaqRT--PCR20/200.7050.648Zhang et al.[@CIT0027]2018hsa_circ_0091579HCCTissuesqRT--PCR30/300.9700.400hsa_circ_16245-1HCCTissuesqRT--PCR30/300.8300.630Shao et al.[@CIT0028]2017hsa_circ_0001895GCTissuesqRT--PCR96/960.6780.857Wang et al.[@CIT0029]2017hsa_circ_0000567CRCTissuesqRT--PCR102/1020.8330.765Zhao et al.[@CIT0030]2018hsa_circ_0081001OSCCSalivaryqRT--PCR90/820.7440.902Fu,et al.[@CIT0031]2017hsa_circ_0004018HCCTissuesqRT--PCR102/1020.7160.815[^2]

Quality assessment {#S0003-S2003}
------------------

A quality assessment of the eligible studies was performed using QUADAS-2 ([Figure 2](#F0002){ref-type="fig"}). The figure depicts the relatively moderate quality of the 32 included studies. Most studies had either low or unclear risks of bias due to a lack of information on patient selection, exclusion criteria, or pre-specified thresholds.Figure 2Quality assessment of the included studies according to QUADAS-2.

Diagnostic accuracy {#S0003-S2004}
-------------------

Heterogeneity among studies was evaluated by examining the threshold and non-threshold effects. In our study, the Spearman correlation coefficient and *P-*value were 0.658 and 0.218, respectively, suggesting that there was no threshold effect. Heterogeneity owing to non-threshold effects was then assessed with *Q-*tests and *I*^2^ statistics. There was significant heterogeneity in the pooled sensitivity (*I*^2^=89.57%, *P*\<0.001) and specificity (*I*^2^=90.88%, *P*\<0.001); thus, a random-effects model was applied to analyze the diagnostic parameters. The pooled sensitivity and specificity were 0.79 (95% CI: 0.73--0.84) and 0.73 (95% CI: 0.67--0.79), respectively ([Figure 3](#F0003){ref-type="fig"}). In addition, the pooled PLR, NLR, and DOR were 2.9 (95% CI: 2.5--3.5), 0.29 (95% CI: 0.24--0.36), and 10 (95% CI: 8--13), respectively. The summary receiver operator characteristic (SROC) curve is shown in [Figure 4](#F0004){ref-type="fig"}; the AUC was 0.83. These results indicated that circRNAs have potential diagnostic value for several cancers.Figure 3Forest plots of sensitivity and specificity of circRNAs for cancer diagnosis. (**A**) Pooled sensitivity for circRNAs. (**B**) Pooled specificity for circRNAs.Figure 4Summary receiver operator characteristic curve for cancer diagnosis.

Subgroup analysis and meta-regression {#S0003-S2005}
-------------------------------------

To explore the potential sources of heterogeneity, subgroup analyses were first performed based on specimen (tissue vs other), case size (≥100 vs \<100), and cancer type (GC vs other) ([Table 2](#T0002){ref-type="table"}). Studies using other samples (plasma or saliva) had better diagnostic accuracy than those using tissue samples for cancer diagnosis, with increased sensitivity (0.75 vs 0.84), decreased NLR (0.33 vs 0.23), increased DOR (9 vs 12), and increased AUC (0.81 vs 0.84). Additionally, studies involving ≥100 cases or GC showed higher sensitivities but lower specificities than those involving \<100 cases or other cancers. However, meta-regression analyses indicated that no methodological covariates affected the diagnostic accuracy of circRNAs (all joint *P*\>0.05).Table 2Results of subgroup analysisSubgroupsStudiesSensitivity\
\[95% CI\]Specificity\
\[95% CI\]PLR\
\[95% CI\]NLR\
\[95% CI\]DOR\
\[95% CI\]AUC\
\[95% CI\]Specimen Tissue200.75\[0.69--0.80\]0.75\[0.69--0.80\]3.0\[2.6--3.5\]0.33\[0.28--0.40\]9\[7--11\]0.81\[0.78--0.85\] Other120.84\[0.72--0.91\]0.70\[0.56--0.82\]2.8\[1.9--4.2\]0.23\[0.14--0.38\]12\[7--23\]0.84\[0.81--0.87\]Case size ≥100170.82\[0.72--0.89\]0.70\[0.61--0.78\]2.8\[2.2--3.5\]0.25\[0.17--0.37\]11\[8--16\]0.82\[0.79--0.85\] \<100150.74\[0.69--0.79\]0.77\[0.69--0.83\]3.2\[2.4--4.2\]0.34\[0.28--0.40\]10\[7--13\]0.81\[0.77--0.84\]Cancer type GC160.80\[0.69--0.87\]0.71\[0.61--0.79\]2.7\[2.1--3.5\]0.29\[0.20--0.41\]9\[6--14\]0.81\[0.78--0.85\] Other160.78\[0.71--0.83\]0.76\[0.70--0.82\]3.3\[2.6--4.0\]0.29\[0.24--0.37\]11\[8--15\]0.84\[0.80--0.87\]Overall320.79\[0.73--0.84\]0.73\[0.67--0.79\]2.9\[2.5--3.5\]0.29\[0.24--0.36\]10\[8--13\]0.83\[0.79--0.86\][^3]

We also analyzed subgroups according to cancer type, and the main results were summarized in [Figure 5](#F0005){ref-type="fig"}. Significant heterogeneity was observed in the GC group (*I^2^*=57.8%, *P*=0.002). No significant heterogeneity was observed in the HCC (*I^2^*=23.0%, *P*=0.254), CRC (*I^2^*=13.9%, *P*=0.313), LAC (*I^2^*=0.0%, *P*=0.379), and BC (*I^2^*=0.0%, *P*=0.517) subgroups. The results suggest that cancer type may act as potential sources of heterogeneity.Figure 5Subgroup analyses according to cancer type.

Sensitivity analysis {#S0003-S2006}
--------------------

To further explain the heterogeneity of individual studies, we performed a sensitivity analysis by removing individual studies. As shown in [Figure 6](#F0006){ref-type="fig"}, no outlier study was identified and the results were relatively stable and reliable.Figure 6Sensitivity analysis of the overall pooled study.

Publication bias {#S0003-S2007}
----------------

Deeks' funnel plot asymmetry tests were applied to estimate publication bias in the meta-analysis (shown in [Figure 7](#F0007){ref-type="fig"}). The results confirmed the lack of significant publication bias across the overall combined diagnostic studies (*P*=0.68, \>0.05).Figure 7Deeks' funnel plot to assess publication bias.**Abbreviation:**ESS, effective sample size.

Discussion {#S0004}
==========

Owing to their closed continuous loop structure, circRNAs are more stable in the extracellular space compared to linear RNAs. This feature makes circRNAs advantageous for use as molecular markers of cancer. The current study comprehensively assessed the diagnostic efficacy of circRNAs for several cancers. The pooled effect showed the relatively high level of diagnostic accuracy of circRNAs, suggesting their potential as effective biomarkers for cancer diagnosis.

CircRNAs have recently been identified as a family of naturally occurring endogenous noncoding RNAs that may regulate gene expression in mammals.[@CIT0032] With the widespread application of bioinformatics and next-generation sequencing technologies, a large number of circRNAs have been sequenced and entered into a database of 32,914 human exonic circRNAs.[@CIT0033] In addition, some circRNAs are related to cancer diagnosis. Previous studies have shown that circRNAs play a crucial role in transcriptional or posttranscriptional regulation of gene expression.[@CIT0034] Moreover, circRNAs, acting as efficient microRNA (miRNA) sponges, can specifically bind to miRNAs and compete with endogenous RNA, strongly suppressing microRNA activity and potentially contributing to tumor progression.[@CIT0003] Furthermore, circRNAs are associated with RNA binding proteins, which play crucial roles in cancer development through dysregulation of transcription or expression.[@CIT0035] Most importantly, circRNAs are more abundant and stable than the corresponding linear RNAs. Recently, a fusion circRNA (F-circEA) was discovered to monitor fusion genes involved in tumorigenesis, which could be a potential novel "liquid biopsy" biomarker in non-small cell lung cancer.[@CIT0036] Li et al first reported on exosomes enriched with stable circRNAs and proposed their potential of circRNAs as a new class of cancer biomarkers.[@CIT0037] These findings suggest that circRNAs may be a promising diagnostic biomarker for cancer.

Our study, comprising 3,016 participants (2,400 cases and 2,295 controls) is the most comprehensive meta-analysis to assess the diagnostic value of circRNAs for various cancers. Two meta-analyses have been published on the diagnostic value of circRNAs. Li et al[@CIT0038] and Wang et al[@CIT0039] reported circRNA AUCs of 0.793 and 0.79, respectively. Compared to their results, our study observed a higher diagnostic efficiency (AUC=0.83). In our meta-analysis, we first conducted a quality assessment of the 32 enrolled studies, which revealed relatively moderate quality. The overall pooled sensitivity, specificity, and AUC of circRNAs for cancer diagnosis were 0.79 (95% CI: 0.73--0.84), 0.73 (95% CI: 0.67--0.79), and 0.83 (95% CI: 0.79--0.86), respectively; higher values than those for traditional plasma-based biomarkers such as CEA and CA19-9.[@CIT0040] In addition, the pooled DOR of circRNAs was 10, suggesting a powerful discriminating capacity of circRNAs for cancer diagnosis. Together, these findings suggest that circRNAs might be effective biomarkers for cancer diagnosis.

The pooled results indicated that there was significant heterogeneity that could impact the accuracy among the overall studies. The Spearman correlation coefficient was 0.658 (*P*=0.218), suggesting that the threshold effect was not the source of heterogeneity. We further performed meta-regression and subgroup analysis. Studies with plasma samples had better diagnostic accuracy, while ≥100 cases or GC showed higher sensitivities than those with \<100 cases or other cancers. The results implied that specimen, case size, and cancer type might influence the diagnostic accuracy; however, the differences were not statistically significant. Sensitivity analysis was also conducted to analyze the heterogeneity, but no outlier studies were found. The heterogeneity could derive from confounding factors and differences in methodology.

The present meta-analysis has several limitations. First, there was significant heterogeneity among the included studies. Although we performed subgroup analysis and meta-regression to explore the sources of heterogeneity, the results did not fully explain the potential heterogeneity. Second, only studies conducted in Asia were included; therefore, the results for other ethnicities might be missed, which may lead to population selection bias. Therefore, additional higher-quality, multicenter, and well-designed studies are required to confirm our findings.

Conclusion {#S0005}
==========

The results of our meta-analysis suggest the potential of circRNAs as biomarkers for the diagnosis of several cancers, with good diagnostic efficiency (AUC=0.83). However, the application of circRNAs for cancer diagnosis requires further validation.
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